Longevity & AgingEli Lilly Bets $1 Billion on Pill That Could Prevent Alzheimer's Before Symptoms Start
Eli Lilly has struck a deal worth up to $1 billion with Swedish biotech AlzeCure Pharma for rights to Alzstatin ACD680, a drug designed to prevent Alzheimer's disease rather than treat it. The compound works by blocking the re-accumulation of amyloid proteins in the brain — the same proteins linked to Alzheimer's progression — without shutting down the enzyme entirely, which caused serious side effects in earlier drug failures. The deal includes $10 million upfront plus milestone payments. ACD680 is still preclinical, but the concept echoes how statins reshaped cardiovascular prevention: a daily pill taken proactively, years before disease appears, to preserve brain health across a lifetime.
